ID   PCAT1_HUMAN             Reviewed;         534 AA.
AC   Q8NF37; Q1HAQ1; Q7Z4G6; Q8N3U7; Q8WUL8; Q9GZW6;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   25-JUL-2006, sequence version 2.
DT   18-JUN-2025, entry version 174.
DE   RecName: Full=Lysophosphatidylcholine acyltransferase 1;
DE            Short=LPC acyltransferase 1;
DE            Short=LPCAT-1;
DE            Short=LysoPC acyltransferase 1;
DE            EC=2.3.1.23 {ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505};
DE   AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase;
DE            EC=2.3.1.51 {ECO:0000250|UniProtKB:Q1HAQ0};
DE   AltName: Full=1-acylglycerophosphocholine O-acyltransferase;
DE   AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase;
DE            EC=2.3.1.25 {ECO:0000250|UniProtKB:Q3TFD2};
DE   AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase;
DE            EC=2.3.1.67 {ECO:0000250|UniProtKB:Q3TFD2};
DE   AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase;
DE            Short=Acetyl-CoA:lyso-PAF acetyltransferase;
DE            Short=Lyso-PAF acetyltransferase;
DE            Short=LysoPAFAT;
DE   AltName: Full=Acyltransferase-like 2;
DE   AltName: Full=Phosphonoformate immuno-associated protein 3;
GN   Name=LPCAT1; Synonyms=AYTL2, PFAAP3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=16704971; DOI=10.1074/jbc.m600225200;
RA   Nakanishi H., Shindou H., Hishikawa D., Harayama T., Ogasawara R.,
RA   Suwabe A., Taguchi R., Shimizu T.;
RT   "Cloning and characterization of mouse lung-type acyl-
RT   CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1): expression in
RT   alveolar type II cells and possible involvement in surfactant production.";
RL   J. Biol. Chem. 281:20140-20147(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 136-534.
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 140-534.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 236-534.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 298-534.
RA   Liu Y., Cheng J., Lu Y.;
RT   "Screening and cloning of a new immuno-associated gene regulated by
RT   phosphonoformate.";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 448-534.
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   IDENTIFICATION.
RX   PubMed=16864775; DOI=10.1073/pnas.0604946103;
RA   Chen X., Hyatt B.A., Mucenski M.L., Mason R.J., Shannon J.M.;
RT   "Identification and characterization of a lysophosphatidylcholine
RT   acyltransferase in alveolar type II cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:11724-11729(2006).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=18156367; DOI=10.1073/pnas.0709737104;
RA   Soupene E., Fyrst H., Kuypers F.A.;
RT   "Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:88-93(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, TOPOLOGY, AND
RP   DI-LYSINE MOTIF.
RX   PubMed=21498505; DOI=10.1074/jbc.m110.202424;
RA   Moessinger C., Kuerschner L., Spandl J., Shevchenko A., Thiele C.;
RT   "Human lysophosphatidylcholine acyltransferases 1 and 2 are located in
RT   lipid droplets where they catalyze the formation of phosphatidylcholine.";
RL   J. Biol. Chem. 286:21330-21339(2011).
RN   [11]
RP   FUNCTION.
RX   PubMed=25491198; DOI=10.1186/s12860-014-0043-3;
RA   Moessinger C., Klizaite K., Steinhagen A., Philippou-Massier J.,
RA   Shevchenko A., Hoch M., Ejsing C.S., Thiele C.;
RT   "Two different pathways of phosphatidylcholine synthesis, the Kennedy
RT   Pathway and the Lands Cycle, differentially regulate cellular
RT   triacylglycerol storage.";
RL   BMC Cell Biol. 15:43-43(2014).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Exhibits acyltransferase activity (PubMed:18156367,
CC       PubMed:21498505). Exhibits acetyltransferase activity (By similarity).
CC       Activity is calcium-independent (By similarity). Catalyzes the
CC       conversion of lysophosphatidylcholine (1-acyl-sn-glycero-3-
CC       phosphocholine or LPC) into phosphatidylcholine (1,2-diacyl-sn-glycero-
CC       3-phosphocholine or PC) (PubMed:18156367, PubMed:21498505). Catalyzes
CC       the conversion 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or
CC       LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA)
CC       by incorporating an acyl moiety at the sn-2 position of the glycerol
CC       backbone (By similarity). Displays a clear preference for saturated
CC       fatty acyl-CoAs, and 1-myristoyl or 1-palmitoyl LPC as acyl donors and
CC       acceptors, respectively (By similarity). Involved in platelet-
CC       activating factor (PAF) biosynthesis by catalyzing the conversion of
CC       the PAF precursor, 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF)
CC       into 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) (By
CC       similarity). May synthesize phosphatidylcholine in pulmonary
CC       surfactant, thereby playing a pivotal role in respiratory physiology
CC       (By similarity). Involved in the regulation of lipid droplet number and
CC       size (PubMed:25491198). {ECO:0000250|UniProtKB:Q3TFD2,
CC       ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505,
CC       ECO:0000269|PubMed:25491198}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + an acyl-CoA = a 1,2-
CC         diacyl-sn-glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:12937,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57643, ChEBI:CHEBI:58168,
CC         ChEBI:CHEBI:58342; EC=2.3.1.23;
CC         Evidence={ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphate + an acyl-CoA = a 1,2-diacyl-
CC         sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:19709,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57970, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:58608; EC=2.3.1.51;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = a 1-O-
CC         alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:18461, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288; EC=2.3.1.67;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-(1Z-alkenyl)-sn-glycero-3-phosphocholine + an acyl-CoA =
CC         a 1-O-(1Z-alkenyl)-2-acyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:10344, ChEBI:CHEBI:57287, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:77286, ChEBI:CHEBI:77287; EC=2.3.1.25;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-acyl-sn-glycero-3-phospho-(1'-sn-glycerol) + an acyl-CoA = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + CoA;
CC         Xref=Rhea:RHEA:33203, ChEBI:CHEBI:57287, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:64716, ChEBI:CHEBI:64840;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33204;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + (9Z)-
CC         octadecenoyl-CoA = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:35991, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:72998, ChEBI:CHEBI:73001;
CC         Evidence={ECO:0000269|PubMed:21498505};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35992;
CC         Evidence={ECO:0000305|PubMed:21498505};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:35983, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35984;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA =
CC         1-O-hexadecyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37811, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:64496, ChEBI:CHEBI:72744;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37812;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-(1Z-alkenyl)-sn-glycero-3-phosphocholine + hexadecanoyl-
CC         CoA = 1-O-(1Z)-alkenyl-2-hexadecanoyl-sn-glycero-3-phosphocholine +
CC         CoA; Xref=Rhea:RHEA:37819, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:77287, ChEBI:CHEBI:77304;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37820;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol) +
CC         hexadecanoyl-CoA = 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'-sn-
CC         glycerol) + CoA; Xref=Rhea:RHEA:35851, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57379, ChEBI:CHEBI:72829, ChEBI:CHEBI:75158;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35852;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-dodecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA =
CC         1-dodecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37511, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:74966, ChEBI:CHEBI:75017;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37512;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-tetradecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1-tetradecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37655, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:64489, ChEBI:CHEBI:75062;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37656;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-octadecyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA =
CC         1-O-octadecyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37839, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:75216, ChEBI:CHEBI:75290;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37840;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1-octadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37527, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:73858, ChEBI:CHEBI:75026;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37528;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine +
CC         hexadecanoyl-CoA = 1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:37383, ChEBI:CHEBI:28610,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57379, ChEBI:CHEBI:74667;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37384;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-eicosanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA =
CC         1-eicosanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37843, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:74968, ChEBI:CHEBI:75294;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37844;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine = 1-
CC         hexadecanoyl-2-hexanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37855, ChEBI:CHEBI:57287, ChEBI:CHEBI:62620,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75301;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37856;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=octanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine = 1-
CC         hexadecanoyl-2-octanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37859, ChEBI:CHEBI:57287, ChEBI:CHEBI:57386,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75302;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37860;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=decanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine = 1-
CC         hexadecanoyl-2-decanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37863, ChEBI:CHEBI:57287, ChEBI:CHEBI:61430,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75300;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37864;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine =
CC         1-hexadecanoyl-2-dodecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37515, ChEBI:CHEBI:57287, ChEBI:CHEBI:57375,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75018;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37516;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=tetradecanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine
CC         = 1-hexadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37867, ChEBI:CHEBI:57287, ChEBI:CHEBI:57385,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75304;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37868;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoyl-CoA + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine = 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-
CC         glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:35995,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73002; Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35996;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA + 1-hexadecanoyl-
CC         sn-glycero-3-phosphocholine = 1-hexadecanoyl-2-
CC         (4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine +
CC         CoA; Xref=Rhea:RHEA:37475, ChEBI:CHEBI:57287, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:74298, ChEBI:CHEBI:74963;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37476;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-
CC         hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37703, ChEBI:CHEBI:57287, ChEBI:CHEBI:57288,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75219;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37704;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=eicosanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine =
CC         1-hexadecanoyl-2-eicosanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:43264, ChEBI:CHEBI:57287, ChEBI:CHEBI:57380,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:82943;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43265;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-O-
CC         hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37719, ChEBI:CHEBI:44811, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57288, ChEBI:CHEBI:64496;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37720;
CC         Evidence={ECO:0000250|UniProtKB:Q3TFD2};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA = 1-
CC         acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37803, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:58168, ChEBI:CHEBI:75279;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37804;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphate + hexadecanoyl-CoA = 1-acyl-2-
CC         hexadecanoyl-sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:33315,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57379, ChEBI:CHEBI:57970,
CC         ChEBI:CHEBI:64862; Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33316;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-acyl-sn-glycero-3-phospho-(1'-sn-glycerol) + hexadecanoyl-
CC         CoA = 1-acyl-2-hexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol) +
CC         CoA; Xref=Rhea:RHEA:37807, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:64840, ChEBI:CHEBI:75280;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37808;
CC         Evidence={ECO:0000250|UniProtKB:Q1HAQ0};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.6 uM for palmitoyl-CoA (in the presence of 1-palmitoyl-LPC as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=4 uM for oleoyl-CoA (in the presence of 1-palmitoyl-LPC as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=7.8 uM for linoleoyl-CoA (in the presence of 1-palmitoyl-LPC as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=4.3 uM for arachidonyl-CoA (in the presence of 1-palmitoyl-LPC as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=6.8 uM for 1-palmitoyl-LPC (in the presence of palmitoyl-CoA as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=27 uM for 1-palmitoyl-LPC (in the presence of oleoyl-CoA as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=44.5 uM for 1-palmitoyl-LPC (in the presence of linoleoyl-CoA as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         KM=9.2 uM for 1-palmitoyl-LPC (in the presence of arachidonyl-CoA as
CC         cosubstrate) {ECO:0000269|PubMed:18156367};
CC         Vmax=2.8 nmol/min/mg enzyme towards palmitoyl-CoA using
CC         1-palmitoyl-LPC as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=5.6 nmol/min/mg enzyme towards oleoyl-CoA using 1-palmitoyl-LPC
CC         as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=11.3 nmol/min/mg enzyme towards linoleoyl-CoA using
CC         1-palmitoyl-LPC as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=4.6 nmol/min/mg enzyme towards arachidonyl-CoA using
CC         1-palmitoyl-LPC as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=1.4 nmol/min/mg enzyme towards 1-palmitoyl-LPC using
CC         palmitoyl-CoA as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=6.8 nmol/min/mg enzyme towards 1-palmitoyl-LPC using oleoyl-CoA
CC         as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=11.8 nmol/min/mg enzyme towards 1-palmitoyl-LPC using
CC         linoleoyl-CoA as cosubstrate {ECO:0000269|PubMed:18156367};
CC         Vmax=3.6 nmol/min/mg enzyme with towards 1-palmitoyl-LPC using
CC         arachidonyl-CoA as cosubstrate {ECO:0000269|PubMed:18156367};
CC       pH dependence:
CC         Optimum pH is 5.5 and 7.5. {ECO:0000269|PubMed:18156367};
CC   -!- PATHWAY: Lipid metabolism; phospholipid metabolism.
CC       {ECO:0000269|PubMed:21498505}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:21498505}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:21498505}. Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:Q3TFD2}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:21498505}. Cell membrane
CC       {ECO:0000305|PubMed:18156367}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:21498505}. Lipid droplet
CC       {ECO:0000269|PubMed:21498505}. Note=May adopt a monotopic topology when
CC       embedded in the lipid monolayer of the lipid droplet, with both termini
CC       exposed to the cytoplasm. {ECO:0000269|PubMed:21498505}.
CC   -!- TISSUE SPECIFICITY: Erythrocytes. {ECO:0000269|PubMed:18156367}.
CC   -!- DOMAIN: The HXXXXD motif is essential for acyltransferase activity and
CC       may constitute the binding site for the phosphate moiety of the
CC       glycerol-3-phosphocholine. {ECO:0000250|UniProtKB:Q3TFD2}.
CC   -!- DOMAIN: The di-lysine motif may confer endoplasmic reticulum
CC       localization. {ECO:0000250|UniProtKB:Q3TFD2}.
CC   -!- SIMILARITY: Belongs to the 1-acyl-sn-glycerol-3-phosphate
CC       acyltransferase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14061.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14065.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB244719; BAE94688.1; -; mRNA.
DR   EMBL; AK090444; BAC03425.1; -; mRNA.
DR   EMBL; BC020166; AAH20166.3; -; mRNA.
DR   EMBL; AK022505; BAB14065.1; ALT_INIT; mRNA.
DR   EMBL; AK022499; BAB14061.1; ALT_INIT; mRNA.
DR   EMBL; AF530061; AAQ09945.1; -; mRNA.
DR   EMBL; AL831864; CAD38556.1; -; mRNA.
DR   CCDS; CCDS3864.1; -.
DR   RefSeq; NP_079106.3; NM_024830.4.
DR   AlphaFoldDB; Q8NF37; -.
DR   SMR; Q8NF37; -.
DR   BioGRID; 122973; 143.
DR   FunCoup; Q8NF37; 1584.
DR   IntAct; Q8NF37; 53.
DR   MINT; Q8NF37; -.
DR   STRING; 9606.ENSP00000283415; -.
DR   ChEMBL; CHEMBL4295903; -.
DR   DrugBank; DB15584; Luteolin.
DR   DrugBank; DB04216; Quercetin.
DR   SwissLipids; SLP:000000295; -.
DR   GlyCosmos; Q8NF37; 2 sites, 1 glycan.
DR   GlyGen; Q8NF37; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q8NF37; -.
DR   PhosphoSitePlus; Q8NF37; -.
DR   SwissPalm; Q8NF37; -.
DR   BioMuta; LPCAT1; -.
DR   DMDM; 110815902; -.
DR   jPOST; Q8NF37; -.
DR   MassIVE; Q8NF37; -.
DR   PaxDb; 9606-ENSP00000283415; -.
DR   PeptideAtlas; Q8NF37; -.
DR   ProteomicsDB; 73259; -.
DR   Pumba; Q8NF37; -.
DR   TopDownProteomics; Q8NF37; -.
DR   Antibodypedia; 1587; 220 antibodies from 28 providers.
DR   DNASU; 79888; -.
DR   Ensembl; ENST00000283415.4; ENSP00000283415.3; ENSG00000153395.11.
DR   Ensembl; ENST00000475622.6; ENSP00000423472.1; ENSG00000153395.11.
DR   GeneID; 79888; -.
DR   KEGG; hsa:79888; -.
DR   MANE-Select; ENST00000283415.4; ENSP00000283415.3; NM_024830.5; NP_079106.3.
DR   UCSC; uc003jcm.4; human.
DR   AGR; HGNC:25718; -.
DR   CTD; 79888; -.
DR   DisGeNET; 79888; -.
DR   GeneCards; LPCAT1; -.
DR   HGNC; HGNC:25718; LPCAT1.
DR   HPA; ENSG00000153395; Tissue enhanced (lung, lymphoid tissue).
DR   MIM; 610472; gene.
DR   OpenTargets; ENSG00000153395; -.
DR   VEuPathDB; HostDB:ENSG00000153395; -.
DR   eggNOG; KOG2898; Eukaryota.
DR   eggNOG; KOG4666; Eukaryota.
DR   GeneTree; ENSGT01030000234574; -.
DR   HOGENOM; CLU_025017_0_1_1; -.
DR   InParanoid; Q8NF37; -.
DR   OMA; TEDDLAC; -.
DR   OrthoDB; 272512at2759; -.
DR   PAN-GO; Q8NF37; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8NF37; -.
DR   BRENDA; 2.3.1.23; 2681.
DR   BRENDA; 2.3.1.51; 2681.
DR   BRENDA; 2.3.1.62; 2681.
DR   PathwayCommons; Q8NF37; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482925; Acyl chain remodelling of PG.
DR   Reactome; R-HSA-1483166; Synthesis of PA.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q8NF37; -.
DR   SIGNOR; Q8NF37; -.
DR   UniPathway; UPA00085; -.
DR   BioGRID-ORCS; 79888; 23 hits in 1163 CRISPR screens.
DR   ChiTaRS; LPCAT1; human.
DR   GenomeRNAi; 79888; -.
DR   Pharos; Q8NF37; Tbio.
DR   PRO; PR:Q8NF37; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q8NF37; protein.
DR   Bgee; ENSG00000153395; Expressed in upper lobe of left lung and 93 other cell types or tissues.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0003841; F:1-acylglycerol-3-phosphate O-acyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0047184; F:1-acylglycerophosphocholine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0047192; F:1-alkylglycerophosphocholine O-acetyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0047191; F:1-alkylglycerophosphocholine O-acyltransferase activity; IEA:Ensembl.
DR   GO; GO:0047144; F:2-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0042171; F:lysophosphatidic acid acyltransferase activity; IBA:GO_Central.
DR   GO; GO:0047159; F:plasmalogen synthase activity; ISS:UniProtKB.
DR   GO; GO:2001246; P:negative regulation of phosphatidylcholine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0036148; P:phosphatidylglycerol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0008654; P:phospholipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0030163; P:protein catabolic process; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   CDD; cd07991; LPLAT_LPCAT1-like; 1.
DR   FunFam; 1.10.238.10:FF:000379; Lysophosphatidylcholine acyltransferase 1; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR045252; LPCAT1-like.
DR   InterPro; IPR002123; Plipid/glycerol_acylTrfase.
DR   PANTHER; PTHR23063:SF57; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 1; 1.
DR   PANTHER; PTHR23063; PHOSPHOLIPID ACYLTRANSFERASE; 1.
DR   Pfam; PF01553; Acyltransferase; 1.
DR   Pfam; PF13833; EF-hand_8; 1.
DR   SMART; SM00054; EFh; 2.
DR   SMART; SM00563; PlsC; 1.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF69593; Glycerol-3-phosphate (1)-acyltransferase; 1.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   neXtProt; NX_Q8NF37; -.
DR   PharmGKB; PA162394232; -.
DR   TreeFam; TF323244; -.
PE   1: Evidence at protein level;
KW   Acyltransferase; Calcium; Cell membrane; Endoplasmic reticulum;
KW   Golgi apparatus; Lipid biosynthesis; Lipid droplet; Lipid metabolism;
KW   Membrane; Metal-binding; Phospholipid biosynthesis;
KW   Phospholipid metabolism; Proteomics identification; Reference proteome;
KW   Repeat; Signal-anchor; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..534
FT                   /note="Lysophosphatidylcholine acyltransferase 1"
FT                   /id="PRO_0000247064"
FT   TOPO_DOM        1..57
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..78
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        79..534
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          379..414
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          451..486
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          512..534
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           135..140
FT                   /note="HXXXXD motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q3TFD2"
FT   MOTIF           531..534
FT                   /note="Di-lysine motif"
FT                   /evidence="ECO:0000305|PubMed:21498505"
FT   COMPBIAS        7..22
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        523..534
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         392
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         394
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         396
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         398
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
FT   BINDING         403
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   534 AA;  59151 MW;  69A9C3AEC698F6BD CRC64;
     MRLRGCGPRA APASSAGASD ARLLAPPGRN PFVHELRLSA LQKAQVALMT LTLFPVRLLV
     AAAMMLLAWP LALVASLGSA EKEPEQPPAL WRKVVDFLLK AIMRTMWFAG GFHRVAVKGR
     QALPTEAAIL TLAPHSSYFD AIPVTMTMSS IVMKAESRDI PIWGTLIQYI RPVFVSRSDQ
     DSRRKTVEEI KRRAQSNGKW PQIMIFPEGT CTNRTCLITF KPGAFIPGAP VQPVVLRYPN
     KLDTITWTWQ GPGALEILWL TLCQFHNQVE IEFLPVYSPS EEEKRNPALY ASNVRRVMAE
     ALGVSVTDYT FEDCQLALAE GQLRLPADTC LLEFARLVRG LGLKPEKLEK DLDRYSERAR
     MKGGEKIGIA EFAASLEVPV SDLLEDMFSL FDESGSGEVD LRECVVALSV VCRPARTLDT
     IQLAFKMYGA QEDGSVGEGD LSCILKTALG VAELTVTDLF RAIDQEEKGK ITFADFHRFA
     EMYPAFAEEY LYPDQTHFES CAETSPAPIP NGFCADFSPE NSDAGRKPVR KKLD
//
